
Key Points
- 01EU advisory panel backs ENFLONSIA for high-risk children up to 24 months
- 02Proposed indication targets RSV prevention through a second season
- 03SMART Phase 3 trial data underpin the expanded EU use request
- 04European Commission decision expected within two months
EU panel supports expanded ENFLONSIA indication
Merck said the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of an expanded indication for ENFLONSIA (clesrovimab). The proposed label would include prevention of respiratory syncytial virus lower respiratory tract disease in children up to 24 months of age at increased risk for severe RSV disease through their second RSV season.
The recommendation would extend ENFLONSIA’s potential use beyond infants born during or entering their first RSV season, adding coverage for high-risk children who remain vulnerable in their second season. The opinion applies to the European Union as well as Iceland, Liechtenstein and Norway, subject to marketing authorization.
Target population and clinical rationale
The expanded indication is aimed at children up to 24 months old who are at increased risk of severe RSV, including those with chronic lung disease, congenital heart disease and certain conditions associated with early or moderate premature birth. For some children, the risk of severe RSV does not end after their first season and can lead to serious bronchiolitis or pneumonia that may require hospitalization.
The Phase 3 SMART study (MK-1654-007) underpins the opinion. The trial enrolled early or moderate preterm infants and infants with chronic lung disease of prematurity or congenital heart disease to evaluate the safety, efficacy and pharmacokinetics of ENFLONSIA over two RSV seasons.
SMART Phase 3 trial details
In the first RSV season of the SMART trial, participants were randomized 1:1 to receive either a 105 mg intramuscular dose of ENFLONSIA or monthly palivizumab injections. In the second season, eligible participants under two years of age with defined risk conditions received an additional open-label 210 mg intramuscular dose of ENFLONSIA.
A total of 276 eligible children received the second-season 210 mg dose, with most recipients having chronic lung disease or congenital heart disease. Results from SMART were presented at the RSVVW’26 conference in February 2026 and published in the New England Journal of Medicine and JAMA Pediatrics.
Regulatory timelines in Europe and the U.S.
The CHMP’s positive opinion will be reviewed by the European Commission, which is expected to issue a final marketing authorization decision within two months. If granted, the expanded indication would allow ENFLONSIA to be used for RSV prevention in eligible high-risk children through their second season across the European Union and certain associated countries.
In the United States, the Food and Drug Administration has accepted a supplemental Biologics License Application seeking to expand ENFLONSIA’s indication to children under two years of age at increased risk for severe RSV disease through their second RSV season. The FDA has set a Prescription Drug User Fee Act target action date of March 22, 2027 for this application.
Current ENFLONSIA approvals and product profile
ENFLONSIA was first approved by the U.S. FDA in June 2025 and by the European Commission in April 2026 for prevention of RSV lower respiratory tract disease in newborns and infants born during or entering their first RSV season. Merck states that ENFLONSIA is now approved in more than 55 countries worldwide, including the United States, Canada, China, Japan and the European Union, for first-season use.
In the United States, ENFLONSIA is an extended half-life monoclonal antibody for passive immunization against RSV lower respiratory tract disease in newborns and infants in their first season. It is administered as a 105 mg intramuscular dose in a prefilled syringe, using the same dose regardless of weight, and is designed to provide protection for five months, a typical RSV season.
Key Takeaways
- 01Merck has cleared a key EU advisory hurdle for extending ENFLONSIA to high-risk children through their second RSV season, but a final decision rests with the European Commission.
- 02The SMART Phase 3 trial’s two-season design and second-season dosing in 276 high-risk children are central to the regulatory case for expanded use.
- 03Parallel EU and U.S. regulatory reviews could broaden ENFLONSIA’s role from first-season infant protection to a longer window of RSV prevention in vulnerable young children.
References
- https://finance.yahoo.com/healthcare/articles/merck-receives-positive-eu-chmp-114000312.html?.tsrc=rss
- https://www.stocktitan.net/news/MRK/merck-receives-positive-eu-chmp-opinion-to-expand-marketing-iof3rnbfp2v9.html
- https://grafa.com/en/news/united-states/merck-enflonsia-positive-eu-opinion-rsv-prevention-24-months
- https://www.investing.com/news/company-news/european-panel-backs-merck-rsv-drug-for-second-season-use-93CH-5024925